2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: (JACC August 2026-1)-Article: 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

Article: 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

Back to course

Pdf Summary

The 2026 AHA/ACC/ADA/ASN guideline introduces cardiovascular-kidney-metabolic (CKM) syndrome as a unified, staged condition linking obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular disease (CVD). It replaces the older obesity guideline and aims to improve prevention, detection, staging, treatment, and follow-up across the life course, including youth and adults.<br /><br />Key recommendations include:<br />- Stage CKM disease using metabolic risk factors, kidney function (eGFR and UACR), and CVD status.<br />- Use the PREVENT equations to estimate 10- and 30-year risk for total CVD, ASCVD, and heart failure.<br />- Routinely assess social determinants of health, obesity measures, lipids, glucose, kidney function, and selected tests for pre-heart failure, MASLD, and sleep apnea.<br />- Use interdisciplinary care with a CKM coordination point person to reduce fragmented care.<br /><br />Treatment priorities depend on stage:<br />- Stage 1: intensive lifestyle change and weight loss are first-line; obesity drugs or metabolic/bariatric surgery may be added.<br />- Stage 2: treat T2D, hypertension, hypertriglyceridemia, and CKD early; use cardioprotective antihyperglycemic agents (especially SGLT2 inhibitors and GLP-1–based therapies) and kidney-protective agents such as RAS inhibitors, SGLT2 inhibitors, finerenone, and selected GLP-1 therapies.<br />- Stage 3: address subclinical atherosclerosis or pre-heart failure with more intensive prevention.<br />- Stage 4: manage established ASCVD, heart failure, or atrial fibrillation while also treating obesity, diabetes, and CKD.<br /><br />The guideline emphasizes weight management, cardioprotective diabetes therapy, kidney protection, and aggressive risk-factor control. It also addresses MASLD, venous thromboembolism, obstructive sleep apnea, pregnancy-related risk, and advanced CKD. Evidence gaps remain, especially around long-term combination therapy, advanced CKD/dialysis, and implementation of team-based care.

Meta Tag

Concept Cardiovascular-Kidney-Metabolic Syndrome

Concept Staging System

Concept AHA PREVENT Cardiovascular Risk Prediction Equations

Concept Stage-Specific Management

Concept Lifestyle Modification

Keywords

cardiovascular-kidney-metabolic syndrome

CKM guideline

obesity

type 2 diabetes

chronic kidney disease

cardiovascular disease

PREVENT equations

SGLT2 inhibitors

GLP-1 therapies

kidney protection

Cardiovascular-Kidney-Metabolic Syndrome

Staging System

AHA PREVENT Cardiovascular Risk Prediction Equations

Stage-Specific Management

Lifestyle Modification